# Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

> **NCT01007864** · PHASE3 · COMPLETED · sponsor: **Desitin Arzneimittel GmbH** · enrollment: 80 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** piribedil
- **DRUG:** pramipexole or ropinirole

## Key facts

- **NCT ID:** NCT01007864
- **Lead sponsor:** Desitin Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007864, "Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01007864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*